BioDelivery Sciences (BDSI) shares have surged in early trading after the company announced that it has signed an agreement with a major U.S. managed care provider securing preferred status for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence. The agreement officially goes into effect on January 1, 2017. BUNAVAIL will share preferred status with another branded product, still a better position than its former non-preferred status. The managed care organization involved covers more than 10.5M lives and has covered more than 140K prescriptions over the past 12 months for buprenorphine products for opioid dependence.